CN117003739A - 含氮杂环化合物及其制备方法和用途 - Google Patents
含氮杂环化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN117003739A CN117003739A CN202210471801.0A CN202210471801A CN117003739A CN 117003739 A CN117003739 A CN 117003739A CN 202210471801 A CN202210471801 A CN 202210471801A CN 117003739 A CN117003739 A CN 117003739A
- Authority
- CN
- China
- Prior art keywords
- arh
- compound
- alkyl
- formula
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Nitrogen-containing heterocyclic compound Chemical class 0.000 title claims abstract description 181
- 238000002360 preparation method Methods 0.000 title claims abstract description 78
- 150000001875 compounds Chemical class 0.000 claims abstract description 207
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 11
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- 125000001188 haloalkyl group Chemical group 0.000 claims description 39
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 31
- 125000000304 alkynyl group Chemical group 0.000 claims description 31
- 229910052799 carbon Inorganic materials 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 23
- 239000000651 prodrug Substances 0.000 claims description 23
- 229940002612 prodrug Drugs 0.000 claims description 23
- 239000012453 solvate Substances 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 13
- 150000001412 amines Chemical class 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 11
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 10
- 208000025966 Neurological disease Diseases 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 6
- 230000006724 microglial activation Effects 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 230000003959 neuroinflammation Effects 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 238000010640 amide synthesis reaction Methods 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 claims description 2
- 206010034010 Parkinsonism Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 2
- 230000000702 anti-platelet effect Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000002025 microglial effect Effects 0.000 abstract description 23
- 238000006243 chemical reaction Methods 0.000 abstract description 21
- 239000002158 endotoxin Substances 0.000 abstract description 9
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 9
- 230000000770 proinflammatory effect Effects 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 230000002757 inflammatory effect Effects 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 230000001681 protective effect Effects 0.000 abstract description 3
- 230000005779 cell damage Effects 0.000 abstract description 2
- 208000037887 cell injury Diseases 0.000 abstract description 2
- 230000001066 destructive effect Effects 0.000 abstract description 2
- 230000007946 glucose deprivation Effects 0.000 abstract description 2
- 230000020411 cell activation Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 38
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
- 125000004432 carbon atom Chemical group C* 0.000 description 25
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 24
- 210000000274 microglia Anatomy 0.000 description 19
- 229940126214 compound 3 Drugs 0.000 description 17
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 239000012442 inert solvent Substances 0.000 description 14
- 125000006239 protecting group Chemical group 0.000 description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 10
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- IZXWCDITFDNEBY-UHFFFAOYSA-N 1-(chloromethyl)-4-fluorobenzene Chemical group FC1=CC=C(CCl)C=C1 IZXWCDITFDNEBY-UHFFFAOYSA-N 0.000 description 7
- CSGQAXNJZHDONX-UHFFFAOYSA-N 4-methyl-6-phenyl-3-(4-pyrimidin-2-ylpiperazin-1-yl)pyridazine;dihydrochloride Chemical compound Cl.Cl.CC1=CC(C=2C=CC=CC=2)=NN=C1N(CC1)CCN1C1=NC=CC=N1 CSGQAXNJZHDONX-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 150000001266 acyl halides Chemical class 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical group CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 description 5
- IRSVDHPYXFLLDS-UHFFFAOYSA-N 2,4-dichloro-1-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1Cl IRSVDHPYXFLLDS-UHFFFAOYSA-N 0.000 description 5
- XUDITEOFEQOSAK-UHFFFAOYSA-N 5-chloro-1h-indole-3-carboxylic acid Chemical compound C1=C(Cl)C=C2C(C(=O)O)=CNC2=C1 XUDITEOFEQOSAK-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 101000605172 Aspergillus niger (strain CBS 513.88 / FGSC A1513) Probable endopolygalacturonase E Proteins 0.000 description 5
- 101000605171 Aspergillus niger Endopolygalacturonase E Proteins 0.000 description 5
- 101000941281 Bos taurus Gastric triacylglycerol lipase Proteins 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 210000001642 activated microglia Anatomy 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
- NYIZWUCXVMFGLS-UHFFFAOYSA-N 1h-indazol-3-yl-(4-pyrimidin-2-ylpiperazin-1-yl)methanone Chemical compound N=1NC2=CC=CC=C2C=1C(=O)N(CC1)CCN1C1=NC=CC=N1 NYIZWUCXVMFGLS-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000002140 halogenating effect Effects 0.000 description 4
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- GIVOVVHLQZSIMC-UHFFFAOYSA-N 1h-indol-2-yl-(4-pyrimidin-2-ylpiperazin-1-yl)methanone Chemical compound C=1C2=CC=CC=C2NC=1C(=O)N(CC1)CCN1C1=NC=CC=N1 GIVOVVHLQZSIMC-UHFFFAOYSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- UJJLDDNKCAHWIT-UHFFFAOYSA-N 4-pyrimidin-2-ylpiperazine-1-carbaldehyde Chemical compound C1CN(C=O)CCN1C1=NC=CC=N1 UJJLDDNKCAHWIT-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 3
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical group COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 2
- YEBJVSLNUMZXRJ-UHFFFAOYSA-N 5-methoxyindole-2-carboxylic acid Chemical compound COC1=CC=C2NC(C(O)=O)=CC2=C1 YEBJVSLNUMZXRJ-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006757 chemical reactions by type Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
- 125000004518 1,2,5-thiadiazol-3-yl group Chemical group S1N=C(C=N1)* 0.000 description 1
- 125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 description 1
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical compound C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 1
- VGISFWWEOGVMED-UHFFFAOYSA-N 1-(chloromethyl)-3-methoxybenzene Chemical group COC1=CC=CC(CCl)=C1 VGISFWWEOGVMED-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- MJZLUSRCSSOHED-UHFFFAOYSA-N 2-(carbamoylamino)propanamide Chemical compound NC(=O)C(C)NC(N)=O MJZLUSRCSSOHED-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KAWYASGZISVRAL-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-benzimidazole Chemical compound C1CCCC2=C1N=CN2 KAWYASGZISVRAL-UHFFFAOYSA-N 0.000 description 1
- URMVFILWXLQJIP-UHFFFAOYSA-N 4,5,6,7-tetrahydro-3h-imidazo[4,5-c]pyridine Chemical compound C1NCCC2=C1NC=N2 URMVFILWXLQJIP-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001077868 Joanna Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 1
- 101710091942 N-formyl peptide receptor 2 Proteins 0.000 description 1
- YKLFSQROPDRLQF-UHFFFAOYSA-N NCCN.C1=CC=CC2=CC=CC=C21 Chemical compound NCCN.C1=CC=CC2=CC=CC=C21 YKLFSQROPDRLQF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N butadiene group Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008496 central nervous system homeostasis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 1
- 101710108492 fMet-Leu-Phe receptor Proteins 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000004536 indazol-1-yl group Chemical group N1(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000004245 indazol-3-yl group Chemical group [H]N1N=C(*)C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000006776 neuronal homeostasis Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 description 1
- 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetraline Natural products C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种式(I)或式(I’)所示的含氮杂环化合物及其制备方法和用途。本发明的化合物对氧糖剥夺复氧(OGD/R)诱导的小胶质细胞损伤具有显著的保护作用;能够抑制脂多糖诱导的小胶质细胞炎症因子释放,促进小胶质细胞从M1(促炎/破坏型)向M2(抗炎/修复型)表型转化,可用于治疗和/或预防与小胶质细胞活化相关的神经系统疾病。
Description
技术领域
本发明涉及一种含氮杂环化合物及其制备方法和用途。具体地,本发明涉及一种能够治疗和/或预防与小胶质细胞活化相关的神经系统疾病的含氮杂环化合物及其制备方法和用途。
背景技术
神经炎性病症是一个复杂的多细胞过程,在多种神经系统疾病中发挥重要作用,包括脑缺血、神经退行性疾病、精神疾病和免疫介导的疾病。脑部的炎症反应以小胶质细胞的激活和表型分化为特征(Stama M L,Joanna S,Lacivita E,et al.Novelureidopropanamide based N-formyl peptide receptor 2(FPR2)agonists withpotential application for central nervous system disorders characterized byneuroinflammation[J].Eur.J.Med.Chem.2017,141: 703-720.)。
小胶质细胞是中枢神经系统常驻的免疫细胞,具有维持中枢神经系统稳态的功能。在生理上,小胶质细胞作为第一道防线保护大脑免受伤害,并帮助维持神经元稳态。当脑部病理性受损时,无论是通过内源性刺激还是外源性刺激,小胶质细胞均变得更具反应性并转化为“激活”状态。激活的小胶质细胞分为M1型(促炎型/破坏型)和M2型(抗炎/修复型)。M1型小胶质细胞通过释放炎症因子和毒性介质(例如一氧化氮、肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和前列腺素E2(PGE2)等) 加重脑损伤的程度。保护性M2型小胶质细胞通过分泌神经保护因子发挥修复脑损伤的作用。激活后的小胶质细胞是动态的,其表型可以发生改变。大量研究认为,通过干预炎症通路上的不同靶点使小胶质细胞的分化趋向于抗炎表型M2型,可达到减少神经细胞死亡、保护神经功能等积极的作用(Anttila JE,Whitaker K W,Wires E S,et al.Role of microglia inischemic focal stroke and recovery:focus on Toll-like receptors[J].Prog.Neuro-Psychoph. 2017,79:3-14;Kun H,Guichen L,Jinlu Y,et al.Receptors,channel proteins,and enzymes involved in microglia-mediated neuroinflammationand treatments by targeting microglia in ischemic stroke[J].Neuroscience.2021,460:167-180.)。鉴于小胶质细胞和其介导的炎症反应在神经系统疾病中的重要作用,研究者们认为通过抑制小胶质细胞介导的炎症反应,抑制小胶质细胞M1型分化和促进M2型分化是治疗神经系统疾病的有效策略。
现有技术曾报道了具有治疗炎性疾病作用的化合物,例如CN1694704A公开了一种用于治疗炎症和过敏性疾病的化合物(1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(1), WO94/21630公开了一种作为多巴胺受体抑制剂的化合物(1H-吲唑-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(2),可用于治疗精神疾病。Minozac是已公开报道的具有小胶质细胞调节活性的潜在药物,目前仍处于临床研究阶段。
现有技术中针对神经炎症,调控小胶质细胞表型分化的药物较少。因此,开发一种新型有效的神经炎症抑制剂,调控小胶质细胞表型分化,对治疗小胶质细胞过度激活相关的神经系统疾病具有重要的临床价值。
发明内容
一方面,本发明提供了一种具有如式(I)或(I’)所示结构的化合物,
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,其中
B1、B2、B3、B4各自独立地选自CH或N;
X选自CH或N;
R1选自
R2、R3、R4、R7各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、 C1-C20卤代烷基、氰基、硝基、C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基、-ORa、-SRa、-CORa、-CO2Ra、-SORa、-SO2Ra、-NRaRb、-CONRaRb、-SO2NRaRb、 -NRaCORb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基、C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基,或者,Ra和Rb与其共同连接的氮原子一起形成5至14元含氮杂环;
R5选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-NRaRb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基,或者,Ra和Rb与其共同连接的氮原子一起形成5至14元含氮杂环;
R6选自任选取代的C1-C20烷基、C2-C20烯基、C2-C20炔基、C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基;其中所述C1-C20烷基、C2-C20烯基、C2-C20炔基任选地被选自以下的基团取代:卤素、羟基、氰基、硝基、C3-C20环烷基、C6-C14芳基、 5至14元杂芳基、5至14元杂环基,所述C3-C20环烷基、C6-C14芳基、5至14元杂芳基、 5至14元杂环基任选地被选自以下的基团取代:C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-CORa、-CO2Ra、-SORa、-SO2Ra、-NRaRb、 -CONRaRb、-SO2NRaRb、-NRaCORb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基,或者,Ra和Rb与其共同连接的氮原子一起形成5至 14元含氮杂环;
Z选自O、S、NR8;
R8选自H、C1-C20烷基;
m、m’、n、p各自独立地为选自0、1、2、3、4、5的整数。
一方面,本发明提供了一种式(I)所示化合物的制备方法。
一方面,本发明还提供了一种药物组合物,其包含本发明所述的式(I)所示化合物或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,和药学上可接受的载体。
另一方面,本发明还提供了本发明所述的式(I)所示的化合物或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物在制备用于治疗和/或预防神经性炎性疾病的药物中的用途。
另一方面,本发明还提供了本发明所述的式(I)所示的化合物或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物在制备用于治疗和/或预防与小胶质细胞激活相关的神经系统疾病的药物中的用途。
另一方面,本发明还提供了一种治疗和/或预防神经性炎性疾病的方法,包括向有需要的患者施用治疗有效量的本发明所述的式(I)所示的化合物或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物。
实验数据表明,与现有技术相比,本发明化合物对于氧糖剥夺复氧(OGD/R)诱导的小胶质细胞(BV2)具有明显更佳的保护作用,更够更加显著地降低脂多糖(LPS)诱导的小胶质细胞炎症反应,促进小胶质细胞从M1(促炎)向M2(抗炎修复)表型转化。因此,本发明的化合物在制备治疗和/或预防与小胶质细胞活化相关的神经系统疾病的药物方面具有更加明显的优势。
附图说明
附图用来提供对本发明的进一步理解,并且构成说明书的一部分,与本发明的实施例一起用于解释本发明,并不构成对本发明的限制。在附图中:
图1示出了化合物I-10对于抑制小胶质细胞M1型分化的影响。OGD/R后I-10处理获得的BV2小胶质细胞中CD16/32和IBA-1标志物的代表性流式细胞仪染色。IBA-1代表活化的小胶质细胞,CD16/32代表M1型小胶质细胞。数据显示为来自三个独立实验(n =3)的平均值±SD。**p<0.01vs对照,##p<0.01vs OGD/R。
图2示出了化合物I-10对于促进小胶质细胞M2型分化的影响。OGD/R后I-10处理获得的BV2小胶质细胞中CD206和IBA-1标志物的代表性流式细胞仪染色。IBA-1 代表活化的小胶质细胞,CD206代表M2型小胶质细胞。数据显示为来自三个独立实验 (n=3)的平均值±SD。**p<0.01vs对照,##p<0.01vs OGD/R。
具体实施方式
定义
如本发明的说明书中所用的,以下的词语和短语通常被认为具有如下阐明的含义,除非在使用这些词语或短语的上下文中另有指明。
如本文中使用的,术语“烷基”是指具有所示数目的碳原子(例如,具有1至20个碳原子,1至10个碳原子,1至8个碳原子,或者1至6个碳原子等)的直链或支链饱和烃基。在一些实施方案中,烷基的实例包括,但不限于甲基、乙基、1-丙基(正丙基)、2- 丙基(异丙基)、1-丁基(正丁基)、2-甲基-1-丙基(异丁基)、2-丁基(仲丁基)、2-甲基-2-丙基(叔丁基)、1-戊基(正戊基)、2-戊基、3-戊基、2-甲基-2-丁基、3-甲基-2-丁基、3-甲基-1-丁基、 2-甲基-1-丁基、1-己基、2-己基、3-己基、2-甲基-2-戊基、3-甲基-2-戊基、4-甲基-2-戊基、 3-甲基-3-戊基、2-甲基-3-戊基、2,3-二甲基-2-丁基、3,3-二甲基-2-丁基、1-庚基、1-辛基、 1-壬基、1-癸基等。
如本文中使用的,术语“烯基”是指具有所示数目的碳原子(例如,具有2至20个碳原子,2至10个碳原子,2至8个碳原子,或者2至6个碳原子等)并具有碳-碳双键(例如1、2或3个碳-碳双键)的单价直链或支链的不饱和烃基。在一些实施方案中,烯基的实例包括,但不限于乙烯基(即-CH=CH2)、丙烯-1-基(即-CH=CHCH3)、丙烯-3-基(或烯丙基,即-CH2CH=CH2)、丙烯-2-基(即-C(CH3)=CH2)、丁二烯基(包括1,2-丁二烯基和1,3-丁二烯基)等。
如本文中使用的,术语“炔基”是指具有所示数目的碳原子(例如,具有2至20个碳原子,2至10个碳原子,2至8个碳原子,或者2至6个碳原子等)并具有碳-碳三键(例如1、2或3个碳-碳三键)的单价直链或支链的不饱和烃基。在一些实施方案中,炔基的实例包括,但不限于乙炔基(即-C≡CH)、炔丙基(即-CH2C≡CH)、丙炔基(即-C≡CCH3) 等。
如本文中使用的,术语“环烷基”是指具有单环或多个稠环或桥环的3至20个碳原子(更典型地具有3至10个碳原子,3至8个碳原子,或者3至6个碳原子)的单价饱和碳环基团。在一些实施方案中,环烷基基团包括单环结构,例如环丙基、环丁基、环戊基、环辛基等,或多环结构,例如金刚烷基和双环[2.2.1]庚烷基,或与芳基基团稠合的环烷基基团,例如茚满等,如果连接点是通过环烷基基团。
如本文中使用的,术语“芳基”是指具有单环(例如,苯基)或多环(例如,联苯基)或多稠(稠合的)环(例如,萘基、芴基和蒽基)的6至14个碳原子(更典型地具有6 至10个碳原子,或者6个碳原子)的芳香族碳环基团。在一些实施方案中,芳基的实例包括,但不限于单环结构例如苯基,或多环结构例如联苯基,或多稠(稠合)环结构例如芴基、萘基、蒽基,或与环烷基基团稠合的芳基基团例如1,2,3,4-四氢萘等,如果连接点是通过芳基基团。
如本文所使用的,术语“杂芳基”是指在环中包含5至14个环原子的单环或多重稠(稠合的)环(例如,包含2个或3个环)的芳族环基团,其中除了碳原子以外,所述环原子还包含至少一个以上选自氧、氮和/或硫的杂原子。如果环是芳族的,则硫和氮原子也可以氧化形式存在。多重稠(稠合的)环杂芳基是由如上定义的单环杂芳基与选自以下的一个或多个环稠合以形成多重稠环系统:杂芳基(以形成例如萘啶基,诸如l,8-萘啶基),杂环(例如形成1,2,3,4-四氢萘啶基,如1,2,3,4-四氢-1,8-萘啶基),碳环(以形成例如5,6,7,8-四氢喹啉基)和芳基(以形成例如吲唑基)。这样的多重稠环系统可以任选地在稠环的碳环或杂环部分上被一个或多个(例如1、2、3或4)氧代基取代。当价数要求允许时,多重稠环系统的环可以通过稠合、螺环和桥连键相互连接。应当理解,多重稠环系统的各个环可以以任何顺序相对于彼此连接。还应理解,多重稠环系统的连接点可以在该多重稠环系统的任何位置,包括多重稠合系统的杂芳基、杂环、芳基或碳环部分。还应理解,杂芳基的连接点可以在杂芳基的任何合适的原子上,包括碳原子和杂原子(例如氮)。示例性杂芳基包括但不限于:吡啶基、吡咯基、吡嗪基、嘧啶基、哒嗪基、吡唑基、噻吩基、吲哚基、咪唑基、噁唑基、异噁唑基、噻唑基、呋喃基、噁二唑基、噻二唑基、喹啉基、异喹啉基、苯并噻唑基、苯并噁唑基、吲唑基、喹喔啉基、喹唑啉基、5,6,7,8-四氢异喹啉基、苯并呋喃基、苯并咪唑基、硫杂茚基、吡咯并[2,3-b]吡啶基、喹唑啉基-4(3H)-酮、三唑基、4,5,6,7-四氢-1H-吲唑基和3b,4,4a,5-四氢-1H-环丙烷[3,4]环戊烷[1,2-c]吡唑基。
如本文所使用的,术语“杂环基”是指具有在环内具有5至14个环原子的单环或者多个稠(稠合的)环或桥环的单基饱和或部分不饱和基团,其中除了碳原子以外,所述环原子还包含至少一个以上选自氧、氮和/或硫的杂原子。杂环基基团的实例包括,但不限于四氢呋喃基、吗啉基、哌啶基、哌嗪基、二氢吡啶基、4,5,6,7-四氢-1H-苯并[d]咪唑、苯并[d]咪唑、4,5,6,7-四氢-1H-咪唑并[4,5-c]吡啶等。
如本文中使用的,术语“卤素”是指氟、溴、氯和碘。
如本文所使用的,术语“卤代烷基”是指其中一个或多个氢原子被卤素取代的烷基,其中烷基如本文所定义。
如本文所使用的,“前药”是在体内给药时通过一个或多个步骤或过程发生代谢或者另外地转化成化合物的生物、药物或治疗活性形式的化合物。为了制造前药,对药物活性化合物进行改性,使得活性化合物可通过代谢过程再生。可以设计前药以改变代谢稳定性或药物的输送特性,从而掩蔽负效应或毒性,从而改善药物的味道或者从而改变药物的其他特性或性能。由于体内的药效过程和药物代谢的知识,一旦知道了药物活性化合物,本领域的技术人员即可设计所述化合物的前药(参见例如Nogrady(1985)Medicinal ChemistryA Biochemical Approach,牛津大学出版社,纽约,第388-392页)。
如本文所使用的,术语“溶剂合物”是指一种或多种溶剂分子与本发明化合物的缔合物或复合物。形成溶剂合物的溶剂的实例包括但不限于水、异丙醇、乙醇、甲醇、DMSO、乙酸乙酯、乙酸和乙醇胺。术语“水合物”是指其中溶剂分子是水的复合物。
如本文中使用的,术语“药学上可接受的盐”是指保留给定化合物的生物有效性和特性的盐,并且所述盐不是在生物学上或在其他方面不期望的。药学上可接受的盐可以从无机酸和有机酸制得。从无机酸衍生的盐包括盐酸盐、氢溴酸盐、硫酸盐、硝酸盐、磷酸盐、碳酸盐、硫酸氢盐、磷酸氢盐、磷酸二氢盐、碳酸氢盐等。从有机酸衍生的盐包括甲酸盐、乙酸盐、丙酸盐、乙醇酸盐、丙酮酸盐、草酸盐、苹果酸盐、丙二酸盐、琥珀酸盐、马来酸盐、富马酸盐、酒石酸盐、柠檬酸盐、苯甲酸盐、肉桂酸盐、扁桃酸盐、甲磺酸盐、乙磺酸盐、对甲苯磺酸盐、水杨酸盐等。
如本文中使用的,术语“羧基保护基团”是合成有机化学领域的技术人员充分了解的,作为可以选择性地安置在合适的羧基官能团上并从其移除的部分。保护基团方法的领域是充分发展的,并且许多羧基保护基团及其使用方法,是本领域技术人员公知的,如关于权威论述中所述的那些,P.G.M.Wuts和T.W.Greene,Greene's Protective Groups inOrganic Synthesis,第4版,(Wiley,2006)。
如本文中使用的,“任选的”是指随后描述的事件或情况可能发生或可能不发生,并且该描述包括其中所述事件或情况发生的情况以及其中它不发生的情况。
如本文所使用的,术语“立体异构体”是指具有相同的化学组成和连接性,但是其原子在空间具有不同取向的化合物,该取向不能通过单键旋转互换。“立体异构体”包括了“非对映异构体”和“对映异构体”。“非对映异构体”是指具有两个或多个手性中心且其分子并非彼此镜像的立体异构体。非对映异构体具有不同的物理性质,如熔点、沸点、光谱特性和反应性。非对映异构体混合物可在高分辨率分析程序(诸如结晶、电泳和色谱法)下进行分离。“对映异构体”是指彼此为非重叠镜像化合物的两种立体异构体。
如本文所使用的,术语“互变异构体”指的是两种(或两种以上)化合物的共存,这些化合物之间的区别只在于一个(或一个以上)活动原子的位置和电子分布,例如酮-烯醇互变异构体。
如本文所使用的,术语“治疗有效量”是指当给予需要这种治疗的哺乳动物时,如下所限定的足以影响治疗的量。治疗有效量将随着被治疗的对象和疾病状况、受试者的重量和年龄、疾病状况的严重性、给药方式等而变化,其可以由本领域的普通技术人员容易地确定。
化合物
在一个实施方案中,本发明提供的化合物为式(II)或式(II’)所示的化合物,
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,
其中:
B1、B2、B3、B4、R2、R3、R4、R5、R6、R7、m、m’、n、p如式(I)和/或式(I’) 中所定义。
在一个实施方案中,R2、R3、R4、R7各自独立地选自H、C1-C20烷基、C2-C20烯基、 C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-CORa、-CO2Ra、-SORa、 -SO2Ra、-NRaRb、-CONRaRb、-SO2NRaRb、-NRaCORb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基、C3-C20环烷基、C6-C14芳基、5至14 元杂芳基、5至14元杂环基,或者,Ra和Rb与其共同连接的氮原子一起形成5至14元含氮杂环。
在一个实施方案中,R2、R3、R4、R7各自独立地选自H、C1-C20烷基、卤素、C1-C20卤代烷基、-ORa、-SRa、-NRaRb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、 C2-C20炔基、C1-C20卤代烷基。
在一个实施方案中,R6选自任选取代的C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基;其中所述C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14 元杂环基任选地被选自以下的基团取代:C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、 C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-CORa、-CO2Ra、-SORa、-SO2Ra、-NRaRb、 -CONRaRb、-SO2NRaRb、-NRaCORb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基,或者,Ra和Rb与其共同连接的氮原子一起形成5至 14元含氮杂环。
在一个实施方案中,R6选自任选取代的C6-C14芳基、5至14元杂芳基;其中所述 C6-C14芳基、5至14元杂芳基任选地被选自以下的基团取代:C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-CORa、-CO2Ra、-SORa、 -SO2Ra、-NRaRb、-CONRaRb、-SO2NRaRb、-NRaCORb;Ra和Rb各自独立地选自H、C1-C20烷基、C1-C20卤代烷基。
在一个实施方案中,R6选自任选取代的苯基、萘基、蒽基、吡咯基、咪唑基、吡唑基、呋喃基、噻吩基、噁唑基、噻唑基、三唑基、吡啶基、嘧啶基、吡嗪基、哒嗪基、吲哚基、吲唑基、喹啉基、异喹啉基、喹唑啉基、异噁唑基、呋喃基、噁二唑基、噻二唑基、苯并噻唑基、苯并噁唑基、喹喔啉基、5,6,7,8-四氢异喹啉基、苯并呋喃基、苯并咪唑基、硫杂茚基、吡咯并[2,3-b]吡啶基、喹唑啉基-4(3H)-酮、4,5,6,7-四氢-1H-吲唑基、3b,4,4a,5- 四氢-1H-环丙烷[3,4]环戊烷[1,2-c]吡唑基;上述基团任选地被选自以下的基团取代:C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-NRaRb; Ra和Rb各自独立地选自H、C1-C20烷基、C1-C20卤代烷基。
在一个实施方案中,R6选自任选取代的苯基、萘基、蒽基、吡咯-1-基、吡咯-2-基、吡咯-3-基、咪唑-1-基、咪唑-2-基、咪唑-4-基、咪唑-5-基、吡唑-1-基、吡唑-3-基、吡唑-4-基、吡唑-5-基、呋喃-2-基、呋喃-3-基、噻吩-2-基、噻吩-3基、噁唑-2-基、噁唑-4-基、噁唑-5-基、噻唑-2-基、噻唑-4-基、噻唑-5-基、三唑基、吡啶-2-基、吡啶-3-基、吡啶-4-基、嘧啶-2-基、嘧啶-4-基、嘧啶-5-基、吡嗪基、哒嗪-3-基、哒嗪-4-基、吲哚-1-基、吲哚-2- 基、吲哚-3-基、吲唑-1-基、吲唑-3-基、喹啉-2-基、喹啉-3-基、喹啉-4-基、异喹啉基、喹唑啉-2-基、喹唑啉-4-基、异噁唑-3-基、异噁唑-4-基、异噁唑-5-基、1,3,4-噁二唑-2-基、 1,2,5-噁二唑-3-基、1,3,4-噻二唑-2-基、1,2,5-噻二唑-3-基、苯并噻唑-2-基、苯并噁唑-2-基、喹喔啉-2-基、5,6,7,8-四氢异喹啉-1-基、5,6,7,8-四氢异喹啉-3-基、5,6,7,8-四氢异喹啉-4- 基、苯并呋喃-2-基、苯并呋喃-3-基、苯并咪唑-2-基、硫杂茚基;上述基团任选地被选自以下的基团取代:C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-NRaRb;Ra和Rb各自独立地选自H、C1-C20烷基、C1-C20卤代烷基。
在一个实施方案中,R5选自H、C1-C20烷基、卤素、C1-C20卤代烷基、氰基、硝基、 -ORa、-SRa、-NRaRb;Ra和Rb各自独立地选自H、C1-C20烷基、C1-C20卤代烷基。
在一个实施方案中,本发明提供的化合物为具有如式(III)、(III’)或(III”)所示结构的化合物
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,其中,B1、 B2、B3、B4、R2、R3、R4、R5、R6、R7、m、m’、n、p如本文中所定义。
在一个实施方案中,本发明提供的化合物为具有如式(IV)、(IV’)或(IV”)所示结构的化合物
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,其中,R2、 R3、R4、R5、R6、R7、m、m’、n、p如本文中所定义。
在一个实施方案中,本发明提供的化合物为具有如式(V)、(V’)或(V”)所示结构的化合物
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,其中,R2、 R3、R4、R5、R6、R7、n、p如本文中所定义。
在一个实施方案中,本发明提供的化合物选自:
/>
/>
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物。
药物组合物和给药
根据本发明提供的化合物通常以药物组合物的形式给药。本发明因此提供药物组合物,其包含本发明提供的化合物作为活性成分以及一种或多种药学上可接受的载体。所述药物组合物可以单独给药或者与其他治疗剂联合给药。这种组合物以本领域熟知的方式制备(例如Reminton’s Pharmaceutical Sciences,Mace Publishing Co.,Philadelphia,PA 17th Ed.(1985);和Modern Pharmaceutics,Marcel Dekker,Inc.3rd Ed.(G.S.Banker&C.T.Rhodes, Eds.)。
药学上可接受的载体可以是固体或液体。其中,固体载体可以是用作赋形剂、稀释剂、甜味剂、增溶剂、润滑剂、粘合剂、片剂崩解剂、稳定剂、防腐剂或包封材料的一种或多种物质。液体载体可以是溶剂或液体分散介质。合适的固体载体包括但不限于例如纤维素、葡萄糖、乳糖、甘露醇、硬脂酸镁、碳酸镁、碳酸钠、糖精钠、蔗糖、糊精、滑石、淀粉、果胶、明胶、黄芪胶、阿拉伯胶、藻酸钠、对羟基苯甲酸酯、甲基纤维素、羧甲基纤维素钠、低熔点蜡、可可脂等。合适的液体载体包括但不限于水、乙醇、多元醇(例如甘油、丙二醇、液体聚乙二醇等)、植物油(例如花生油、棉籽油、红花油、芝麻油、橄榄油、玉米油和大豆油)、甘油酯、琼脂、无热原水、等渗盐水、林格溶液及其混合物。
本发明的药物组合物可以经由动脉注射、静脉注射、腹腔内、肠胃外、肌肉内、皮下、口服、局部单剂量或多剂量给药。
依据不同的给药途径,本发明的药物组合物可以制备成不同的剂型,例如当用于口服使用时,本发明的药物组合物可以制备成片剂、颗粒剂、溶液剂、锭剂、含片、水性或油性混悬剂、可分散的粉剂或颗粒剂、乳剂、硬或软胶囊剂、糖浆剂或酏剂;当用于注射使用时,本发明的药物组合物可以制备成无菌注射制剂的形式,例如无菌注射用水性或油性悬浮液;当用于局部给药使用时,本发明的药物组合物还可以制备成适用于眼内、肺内、鼻内或透皮给药的制剂例如滴鼻剂、滴眼液、鼻喷剂、气雾剂、透皮贴剂等制剂。可以根据本领域已知用于制造药物组合物的任何方法来制备本发明的药物组合物。
本发明化合物的有效剂量至少取决于所治疗病症的性质、毒性、化合物是否正在预防性使用(较低剂量)或针对活性病毒感染、递送方法和药物制剂,并且将由临床医师使用常规剂量递增研究确定。可以预期每天每千克体重约0.0001至约100mg;通常为每天每千克体重约0.01至约10mg;更典型地,每天每千克体重约0.01至约5mg;最典型的是每天每千克体重约0.05至约0.5mg。例如,约70kg体重的成年人的每日候选剂量将在1mg至 1000mg的范围内,优选在5mg至500mg的范围内,并且可以采取单剂量或多剂量的形式。
本发明的药物组合物还可以包含另外的治疗剂,该治疗剂可用于治疗治疗神经相关疾病,包括但不限于溶栓药物、NMDA受体拮抗剂、抗血小板聚集药物、抗氧化药物、抗凝血药物和抗凋亡药物。
适应症
本发明的化合物可用于预防和/或治疗神经性炎性疾病的药物中的用途。
本发明的化合物可用于预防和/或治疗与小胶质细胞活化相关的神经系统疾病。其中,与小胶质细胞激活相关的神经系统疾病包括缺血性脑卒中、后循环脑缺血、缺血再灌注损伤、肌萎缩性侧索硬化、癫痫、Creutzfeldt-Jakob病、唐氏综合症、扩散性Lewy Body病、亨廷顿病、阿尔兹海默症、多发性硬化、多系统萎缩症、帕金森综合征、原发性脊髓侧索硬化外周神经病、糖尿病性神经病变等。
制备方法
本发明的化合物可以使用本文中公开的方法及其修改方式以及本领域熟知的制备方法制备。本发明的化合物的典型实施方式可以使用以下通用反应流程来实现。通过使用具有类似结构的其它替代原料可以修改通用反应流程从而获得相应不同的产物。原料典型地由商业来源获得或者使用已知的公开的方法合成。
在反应式I中示出了式(II)所示化合物的制备。
反应式I
式(II-a)所示化合物与式(1)所示的胺在适合形成酰胺的条件下反应得到式(II)所示的酰胺。例如,向式(II-a)所示的化合物与式(1)所示的胺在惰性溶剂中的混合物中加入缩合剂(例如2-(7-氮杂-1H-苯并三唑-1-基)-1,1,3,3-四甲基脲鎓六氟磷酸盐(HATU)、二环己基碳二亚胺(DCC)、二异丙基碳二亚胺(DIC)、1-(3-二甲胺基丙基)-3- 乙基碳二亚胺(EDCI)和1-羟基苯并三唑(HOBt)等)和碱(例如N-甲基吗啉、4-二甲基氨基吡啶、三乙胺、二异丙基乙胺等),反应得到式(II)所示化合物;或者,首先将式 (II-a)所示的化合物与卤化试剂(例如草酰氯、亚磺酰氯等)在惰性溶剂中反应生成酰卤,然后再与式(1)所示的胺在碱性条件下(例如N-甲基吗啉、4-二甲基氨基吡啶、三乙胺、二异丙基乙胺等)反应得到式(II)所示化合物;或者,首先将式(II-a)所示的化合物与酰卤化合物(例如甲磺酰氯、对硝基苯磺酰氯等)在惰性溶剂中反应生成活泼酯,然后再与式(1)所示的胺在碱性条件下(例如N-甲基吗啉、4-二甲基氨基吡啶、三乙胺、二异丙基乙胺等)反应得到式(II)所示化合物;或者,首先将式(II-a)所示的化合物与酸酐化合物(例如乙酸酐、三氟乙酸酐等)在惰性溶剂中反应生成混合酸酐化合物,然后再与式(1)所示的胺在碱性条件下(例如N-甲基吗啉、4-二甲基氨基吡啶、三乙胺、二异丙基乙胺等)反应得到式(II)所示化合物。当反应完成时,通过常规手段可以获得纯的式(II)所示化合物。
反应式IA示出了式(II-a)所示化合物的制备。
反应式IA
将式(II-b)所示的化合物在适合脱掉R’基团的条件下反应得到式(II-a)所示的化合物,其中R’是羧基保护基团。例如,当R’为烷基时,可以在碱性条件下(例如氢氧化钠、碳酸钠、氨水等)水解式(II-b)所示的化合物,然后调节pH值得到式(II-a)所示的化合物;或者,当R’为苄基时,可以在钯碳催化剂存在下氢化式(II-b)所示的化合物得到式(II-a)所示的化合物。
反应式IB示出了式(II-b)所示化合物的制备。
反应式IB
将式(II-c)所示的化合物与式(2)所示的化合物在惰性溶剂中(例如N,N-二甲基甲酰胺)在强碱存在下反应得到式(II-b)所示的化合物,其中Z是离去基团例如氯、溴、碘、甲磺酰基、对甲苯磺酰基等。强碱的实例包括但不限于与氢化钠(NaH)、正丁基锂 (n-BuLi)、六甲基二硅氨基钠(NaHMDS)、六甲基二硅氨基锂(LiHMDS)、二异丙基氨基锂(LDA)等。当反应完成时,通过常规手段可以获得纯的式(II-b)所示的化合物。
反应式IC
将式(II-d)所示的化合物在惰性溶剂中与羧基保护基团试剂反应得到式(II-c)所示的化合物,其中R’是羧基保护基团。例如,可以首先将式(II-d)所示的化合物与卤化试剂(例如草酰氯、亚磺酰氯等)在惰性溶剂中反应生成酰卤,然后再与羧基保护基试剂R’OH反应得到式(II-c)所示的化合物;或者,在酸性条件下,将式(II-d)所示的化合物与羧基保护基试剂R’OH直接反应得到式(II-c)所示的化合物。
反应式II示出了式(II’)所示化合物的制备。
反应式II
/>
式(II’-a)所示化合物与式(1)所示的胺在适合形成酰胺的条件下反应得到式(II’) 所示的酰胺。例如,向式(II’-a)所示的化合物与式(1)所示的胺在惰性溶剂中的混合物中加入缩合剂(例如2-(7-氮杂-1H-苯并三唑-1-基)-1,1,3,3-四甲基脲鎓六氟磷酸盐(HATU)、二环己基碳二亚胺(DCC)、二异丙基碳二亚胺(DIC)、1-(3-二甲胺基丙基)-3- 乙基碳二亚胺(EDCI)和1-羟基苯并三唑(HOBt)等)和碱(例如N-甲基吗啉、4-二甲基氨基吡啶、三乙胺、二异丙基乙胺等),反应得到式(II’)所示化合物;或者,首先将式 (II’-a)所示的化合物与卤化试剂(例如草酰氯、亚磺酰氯等)在惰性溶剂中反应生成酰卤,然后再与式(1)所示的胺在碱性条件下(例如N-甲基吗啉、4-二甲基氨基吡啶、三乙胺、二异丙基乙胺等)反应得到式(II’)所示化合物;或者,首先将式(II’-a)所示的化合物与酰卤化合物(例如甲磺酰氯、对硝基苯磺酰氯等)在惰性溶剂中反应生成活泼酯,然后再与式(1)所示的胺在碱性条件下(例如N-甲基吗啉、4-二甲基氨基吡啶、三乙胺、二异丙基乙胺等)反应得到式(II’)所示化合物;或者,首先将式(II’-a)所示的化合物与酸酐化合物(例如乙酸酐、三氟乙酸酐等)在惰性溶剂中反应生成混合酸酐化合物,然后再与式(1)所示的胺在碱性条件下(例如N-甲基吗啉、4-二甲基氨基吡啶、三乙胺、二异丙基乙胺等)反应得到式(II’)所示化合物。当反应完成时,通过常规手段可以获得纯的式(II’)所示化合物。
反应式IIA示出了式(II’-a)所示的化合物的制备。
反应式IIA
将式(II’-b)所示的化合物在适合脱掉R’基团的条件下反应得到式(II’-a)所示的化合物,其中R’是羧基保护基团。例如,当R’为烷基时,可以在碱性条件下(例如氢氧化钠、碳酸钠、氨水等)水解式(II’-b)所示的化合物,然后调节pH值得到式(II’-a)所示的化合物;或者,当R’为苄基时,可以在钯碳催化剂存在下氢化式(II’-b)所示的化合物得到式(II’-a)所示的化合物。
反应式IIB示出了式(II’-b)所示的化合物的制备。
反应式IIB
将式(II’-c)所示的化合物与式(2)所示的化合物在惰性溶剂中(例如N,N-二甲基甲酰胺)在强碱存在下反应得到式(II’-b)所示的化合物,其中Z是离去基团例如氯、溴、碘、甲磺酰基、对甲苯磺酰基等。强碱的实例包括但不限于与氢化钠(NaH)、正丁基锂 (n-BuLi)、六甲基二硅氨基钠(NaHMDS)、六甲基二硅氨基锂(LiHMDS)、二异丙基氨基锂(LDA)等。当反应完成时,通过常规手段可以获得纯的式(II’-b)所示的化合物。
反应式IIC示出了式(II’-c)所示的化合物的制备。
反应式IIC
将式(II’-d)所示的化合物在惰性溶剂中与羧基保护基团试剂反应得到式(II’-c)所示的化合物,其中R’是羧基保护基团。例如,可以首先将式(II’-d)所示的化合物与卤化试剂(例如草酰氯、亚磺酰氯等)在惰性溶剂中反应生成酰卤,然后再与羧基保护基试剂R’OH反应得到式(II’-c)所示的化合物;或者,在酸性条件下,将式(II’-d)所示的化合物与羧基保护基试剂R’OH直接反应得到式(II’-c)所示的化合物。
提供下列实施例以说明本发明化合物的制备,但不以任何方式限制本发明。
实施例1:化合物(5-氯-1-(4-氟苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-1) 的制备
步骤1在装有30ml甲醇溶液的圆底烧瓶中加入化合物3(5g,25.6mmol),冰浴条件下逐滴滴加SOCl2溶液(3.7g,30.8mmol)。滴加完毕后升温至75℃回流搅拌反应3h。减压蒸除溶剂,再用无水二氯甲烷带蒸三次,减压蒸干,残余物经硅胶柱色谱法[V石油醚:V乙酸乙酯=1:1]纯化,得到为黄色固体的中间体4(4.46g),收率89%。
步骤2在100mL圆底烧瓶中依次加入中间体4(1.00g,4.78mmol)、4-氟氯苄(1.38g,9.56mmol)和20mL DMF,分三批加入NaH(0.57g,14.34mmol)(60%分散中矿物油中)。加毕,于室温下反应2.5h,然后加水淬灭反应,并用乙酸调节溶液pH值至4~5,析出大量固体,过滤,滤饼用水洗涤三次,干燥滤饼,得到为白色固体的中间体5(0.89g)。不经纯化直接用于下一步反应。
步骤3将步骤2中得到的中间体5溶于50ml甲醇中,升温至75℃,待固体完全溶解,加入10%NaOH(0.56g,13.95mmol)水溶液,回流反应2.5h。冰浴冷却下滴加37%盐酸溶液酸化,减压抽滤,干燥,得到为白色固体的中间体6(0.62g),收率77.6%。
步骤4在50mL圆底烧瓶中依次加入中间体6(0.62g,2.17mmol)、EDCI(0.62g,3.26mmol)、HOBt(0.44g,3.26mmol)和20mL DMF,于室温下反应30min,然后加入TEA(0.33g,3.26mmol)和1-(嘧啶-2-基)哌嗪(0.72g,4.34mmol),于40℃下反应5h。反应完成后,将反应液冷却至室温,加入蒸馏水(25mL),然后用二氯甲烷(3×25mL)萃取,合并有机相,合并的有机相用饱和食盐水(3×50mL)洗涤,无水Na2SO4干燥,减压抽滤,将滤液蒸除溶剂得到乳白色固体,经硅胶柱层析[V石油醚:V乙酸乙酯=3:1]纯化,得到白色固体状实施例1化合物(I-1)(0.62g),收率63.0%。m.p.167.0℃-168.2℃;1H NMR(400MHz, DMSO-d6)δ8.38(d,J=4.7Hz,2H ArH),7.72-7.64(m,2H ArH),7.25(d,J=8.7Hz,1H ArH),7.10(dd,J=15.9,7.1Hz,4H ArH),6.77(s,1H ArH),6.67(t,J=4.7Hz,1H ArH),5.51 (s,2H NCH2),3.58(m,8H哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.35,161.90(JC-F= 243Hz),161.48,158.45,135.98,134.61(JC-F=3Hz),133.46,129.58(JC-F=8Hz),127.70, 125.33,123.71,121.02,115.83(JC-F=22Hz),112.89,111.05,103.93,46.84,43.58.HRMS (m/z):[M+H]+C24H21ClFN5O:理论值:450.1497,实测值450.1485.
实施例2:化合物(5-氯-1-(4-甲氧基苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮 (I-2)的制备
参考实施例1的制备方法,将4-氟氯苄替换为4-甲氧基氯苄,制得白色固体状化合物 I-2,最后一步收率61.3%。m.p.130.4℃-132.1℃;1H NMR(400MHz,DMSO-d6)δ8.38(d, J=4.7Hz,2H,ArH),7.71-7.66(m,2H,ArH),7.24(dd,J=8.9,2.0Hz,1H,ArH),7.06-7.02(m,2H,ArH),6.83-6.79(m,2H,ArH),6.73(s,1H,ArH),6.67(t,J=4.7Hz,1H,ArH),5.44(s,2H,NCH2),3.67(s,3H,OCH3),3.62-3.43(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ 162.47,161.54,159.11,158.44,135.98,133.50,130.35,129.00,127.65,125.17,123.54,120.93,114.45,112.91,111.07,103.68,55.46,46.95,43.54.ESI-HRMS(m/z):[M+H]+C25H24ClN5O2:理论值462.1697,实测值462.1685.
实施例3:化合物(5-氯-1-(3-氟苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-3) 的制备
参考实施例1的制备方法,将4-氟氯苄替换为3-氟氯苄,制得白色固体状化合物I-3,最后一步收率63.2%。m.p.164.6℃-166.0℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.7Hz,2H,ArH),7.73(d,J=1.9Hz,1H,ArH),7.65(d,J=8.9Hz,1H,ArH),7.35-7.29(m,1H,ArH),7.26(dd,J=8.8,2.0Hz,1H,ArH),7.05(td,J=8.7,2.3Hz,1H,ArH),6.95-6.89(m, 2H,ArH),6.80(s,1H,ArH),6.68(t,J=4.7Hz,1H,ArH),5.56(s,2H,NCH2),3.80-3.48(m, 8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.63(1JC-F=242.6Hz),162.25,161.46,158.46,141.30(3JC-F=7.1Hz),136.01,133.43,131.11(3JC-F=8.2Hz),127.69,125.41,123.80, 123.46(4JC-F=2.7Hz),121.08,114.73(2JC-F=20.7Hz),114.29(2JC-F=21.7Hz),112.88, 111.06,104.06,47.10,43.59.ESI-HRMS(m/z):[M+H]+C24H21ClFN5O:理论值450.1497,实测值450.1484.
实施例4:化合物(5-氯-1-(3-甲氧基苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮 (I-4)的制备
参考实施例1的制备方法,将4-氟氯苄替换为3-甲氧基氯苄,制得白色固体状化合物 I-4,最后一步收率61.3%。m.p.154.9℃-155.7℃;1H NMR(400MHz,DMSO-d6)δ8.38(d, J=4.7Hz,2H,ArH),7.71(d,J=1.9Hz,1H,ArH),7.67(d,J=8.9Hz,1H,ArH),7.25(dd,J=8.8,2.1Hz,1H,ArH),7.17(t,J=7.9Hz,1H,ArH),6.78-6.74(m,2H,ArH),6.69-6.66(m,2H,ArH),6.60(d,J=7.6Hz,1H,ArH),5.50(s,2H,NCH2),3.66(s,3H,OCH3),3.64-3.42(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.34,161.50,159.80,158.46,139.95,136.09,133.53,130.24,127.62,125.25,123.65,120.98,119.53,113.70,112.91,112.86,111.07,103.82, 55.42,47.41,43.54.ESI-HRMS(m/z):[M+H]+C25H24ClN5O2:理论值462.1697,实测值 462.1677.
实施例5:化合物(5-氯-1-(2,4-二氯苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-5)的制备
参考实施例1的制备方法,将4-氟氯苄替换为2,4-二氯氯苄,制得白色固体状化合物 I-5,最后一步收率63.5%。m.p.146.2℃-148.0℃;1H NMR(400MHz,DMSO-d6)δ8.39(d, J=4.7Hz,2H,ArH),7.76(d,J=1.9Hz,1H,ArH),7.64(d,J=2.0Hz,1H,ArH),7.55(d,J=8.8Hz,1H,ArH),7.31-7.25(m,2H,ArH),6.86(s,1H,ArH),6.69(t,J=4.7Hz,1H,ArH),6.55(d,J=8.4Hz,1H,ArH),5.61(s,2H,NCH2),3.70-3.56(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.00,161.50,158.45,136.23,134.89,133.41,133.18,133.00,130.03,129.28,128.03,127.63,125.56,124.01,121.21,112.80,111.09,104.45,45.38,43.65.ESI-HRMS(m/z):[M+H]+C24H20Cl3N5O:理论值500.0812,实测值500.0801.
实施例6:化合物(5-氯-1-(2-氟苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-6) 的制备
参考实施例1的制备方法,将4-氟氯苄替换为2-氟氯苄,制得白色固体状化合物I-6,最后一步收率65.3%。m.p.217.6℃-219.2℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.7,2H,ArH),7.71(d,J=2.0Hz,1H,ArH),7.67(d,J=8.9Hz,1H,ArH),7.31-7.23(m,2H,ArH),7.20-7.13(m,1H,ArH),7.08(td,J=7.5,1.0Hz,1H,ArH),6.94(td,J=7.7,1.4Hz,1H, ArH),6.78(s,1H,ArH),6.67(t,J=4.7Hz,1H,ArH),5.62(s,2H,NCH2),3.80-3.42(m,8H, 哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.26,161.46,160.46(1JC-F=244.2Hz),158.46, 136.19,133.36,130.17(3JC-F=8.1Hz),129.92(3JC-F=4.0Hz),127.54,125.33,125.13(2JC-F= 20.4Hz),125.07(4JC-F=2.5Hz),123.75,121.03,115.88(2JC-F=20.9Hz),112.81,111.04, 104.18,43.53,41.84,41.80.ESI-HRMS(m/z):[M+H]+C24H21ClFN5O:理论值450.1497,实测值450.1481.
实施例7:化合物(5-氯-1-(2-甲氧基苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮 (I-7)的制备
参考实施例1的制备方法,将4-氟氯苄替换为2-甲氧基氯苄,制得白色固体状化合物 I-7,最后一步收率63.2%。m.p.219.0℃-220.4℃;1H NMR(400MHz,DMSO-d6)δ8.37(d, J=4.7Hz,2H,ArH),7.69(d,J=2.0Hz,1H,ArH),7.56(d,J=8.9Hz,1H,ArH),7.24-7.17(m,2H,ArH),6.97(d,J=8.0Hz,1H,ArH),6.80-6.76(m,1H,ArH),6.75(s,1H,ArH),6.67(t,J=4.7Hz,1H,ArH),6.62-6.58(m,1H,ArH),5.49(s,2H,NCH2),3.73(s,3H,OCH3),3.68-3.41(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.41,161.45,158.47,157.16,136.32,133.73,129.27,128.20,127.47,126.01,125.05,123.45,120.85,120.74,113.05,111.37,111.03, 103.63,55.95,43.59,42.97.ESI-HRMS(m/z):[M+H]+C25H24ClN5O2:理论值462.1697,实测值462.1679.
实施例8:化合物5-氯-1-(4-氯苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-8) 的制备
参考实施例1的制备方法,将4-氟氯苄替换为4-氯氯苄,制得白色固体状化合物I-8,最后一步收率61.1%。m.p.139.0℃-140.5℃;1H NMR(400MHz,DMSO-d6)δ8.38(d,J=4.7Hz,2H,ArH),7.71(d,J=2.0Hz,1H,ArH),7.63(d,J=8.9Hz,1H,ArH),7.35-7.31(m,2H,ArH),7.25(dd,J=8.8,2.1Hz,1H,ArH),7.11-7.07(m,2H,ArH),6.78(s,1H,ArH),6.67(t,J=4.7Hz,1H,ArH),5.52(s,2H,NCH2),3.77-3.48(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.27,161.51,158.45,137.42,136.00,133.45,132.52,129.35,129.00,127.70, 125.38,123.76,121.06,112.87,111.06,104.01,46.94,43.62.ESI-HRMS(m/z):[M+H]+ C24H21Cl2N5O:理论值466.1201,实测值466.1185.
实施例9:化合物(5-氯-1-(4-(三氟甲基)苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基) 甲酮(I-9)的制备
参考实施例1的制备方法,将4-氟氯苄替换为4-三氟甲基氯苄,制得白色固体状化合物I-9,最后一步收率58.1%。m.p.170.9℃-172.1℃;1H NMR(400MHz,DMSO-d6)δ8.38 (d,J=4.7Hz,2H,ArH),7.74(d,J=1.9Hz,1H,ArH),7.67-7.62(m,3H,ArH),7.30-7.23(m, 3H,ArH),6.82(s,1H,ArH),6.68(t,J=4.7Hz,1H,ArH),5.65(s,2H,NCH2),3.80-3.54(m, 8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.15,161.52,158.41,143.23,136.08, 133.40,128.50(2JC-F=31.6Hz),128.15,127.70,126.59(3JC-F=221.9Hz),125.95(1JC-F=3.8 Hz),125.48,123.88,121.12,112.83,111.06,104.19,47.25,43.64.ESI-HRMS(m/z):[M+H]+C25H21ClF3N5O:理论值500.1465,实测值500.1444.
实施例10:化合物(1-(4-氟苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-10)的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲哚-2-甲酸,制得白色固体状化合物I-10,0.74g,最后一步收率62.9%;m.p.135.3℃-137.1℃;1H NMR(400MHz,DMSO-d6)δ8.38(d,J=4.7Hz,2H,ArH),7.67-7.55(m,2H,ArH),7.24(t,J=7.3Hz,1H,ArH),7.17-7.05(m,5H,ArH),6.78(s,1H,ArH),6.67(t,J=4.7Hz,1H,ArH),5.52(s,2H,NCH2),3.76-3.52(m,8H,哌嗪–H).13C NMR(100MHz,DMSO-d6)δ162.84,161.84(1JC-F=241.7Hz),161.50,158.45,137.52,134.99(4JC-F=3.1Hz),131.88,129.55(3JC-F=8.3Hz),126.60,123.75,121.96,120.76,115.76(2JC-F=21.3Hz),111.15,111.03,104.51,46.59,43.64. ESI-HRMS(m/z):[M+H]+C24H22FN5O:理论值416.1887,实测值416.1876.
实施例11:化合物(1-(4-甲氧基苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-11) 的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲哚-2-甲酸,将4-氟氯苄替换为4-甲氧基氯苄,制得白色固体状化合物I-11,最后一步收率55.5%。m.p. 132.3℃-133.9℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.7Hz,2H,ArH),7.65-7.62 (m,2H,ArH),7.27-7.22(m,1H,ArH),7.13-7.09(m,1H,ArH),7.06(d,J=8.7Hz,2H,ArH), 6.81(d,J=8.7Hz,2H,ArH),6.75(s,1H,ArH),6.68(t,J=4.7Hz,1H,ArH),5.46(s,2H, NCH2),3.67(s,3H,OCH3),3.64-3.50(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ 162.97,161.56,159.03,158.44,137.53,131.93,130.73,128.98,126.56,123.59,121.87,120.61, 114.39,111.19,111.04,104.25,55.44,46.68,43.61.ESI-HRMS(m/z):[M+H]+C25H25N5O2: 理论值428.2087,实测值428.2070.
实施例12:化合物(1-(3-氟苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-12)的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲哚-2-甲酸,将4-氟氯苄替换为3-氟氯苄,制得白色固体状化合物I-12,最后一步收率52.3%。m.p.161.5℃-163.0℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.7Hz,2H,ArH),7.66(d,J=7.9Hz,1H,ArH), 7.59(d,J=8.3Hz,1H,ArH),7.34-7.23(m,2H,ArH),7.13(t,J=7.4Hz,1H,ArH),7.03(td, J=8.3,2.1Hz,1H,ArH),6.95-6.90(m,2H,ArH),6.82(s,1H,ArH),6.67(t,J=4.7Hz,1H,ArH),5.57(s,2H,NCH2),3.84-3.50(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ 162.73,162.63(1JC-F=242.5Hz),161.48,158.46,141.70(3JC-F=7.0Hz),137.55,131.86, 131.03(3JC-F=8.3Hz),126.58,123.84,123.46(4JC-F=2.8Hz),122.01,120.85,114.59(2JC-F=20.7Hz),114.25(2JC-F=21.6Hz),111.14,111.04,104.64,46.87,43.64.ESI-HRMS(m/z):[M+H]+C24H22FN5O:理论值416.1887,实测值416.1875.
实施例13:化合物(1-(3-甲氧基苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-13) 的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲哚-2-甲酸,将4-氟氯苄替换为3-甲氧基氯苄,制得白色固体状化合物I-13,最后一步收率58.3%。m.p. 131.2℃-132.7℃;1H NMR(400MHz,DMSO-d6)δ8.38(d,J=4.8Hz,2H,ArH),7.65-7.59 (m,2H,ArH),7.26-7.22(m,1H,ArH),7.18-7.09(m,2H,ArH),6.77(s,1H,ArH),6.76-6.72 (m,1H,ArH),6.68(s,1H,ArH),6.67-6.65(m,1H,ArH),6.62(d,J=7.7Hz,1H,ArH),5.50 (s,2H,NCH2),3.70-3.63(m,3H,OCH3),3.63-3.44(m,8H,哌嗪-H).13C NMR(100MHz, DMSO-d6)δ162.85,161.53,159.79,158.45,140.34,137.65,131.97,130.16,126.53,123.69, 121.91,120.70,119.56,113.72,112.71,111.18,111.04,104.39,55.40,47.16,43.58. ESI-HRMS(m/z):[M+H]+C25H25N5O2:理论值428.2087,实测值428.2073.
实施例14:化合物(1-(2,4-二氯苄基)-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-14) 的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲哚-2-甲酸,将4-氟氯苄替换为2,4-二氯氯苄,制得白色固体状化合物I-14,最后一步收率61.3%。m.p. 133.0℃-134.8℃;1H NMR(400MHz,DMSO-d6)δ8.38(d,J=4.7Hz,2H,ArH),7.69(d,J= 7.8Hz,1H,ArH),7.63(d,J=1.2Hz,1H,ArH),7.46(d,J=8.3Hz,1H,ArH),7.28-7.22(m, 2H,ArH),7.15(t,J=7.4Hz,1H,ArH),6.88(s,1H,ArH),6.67(t,J=4.6Hz,1H,ArH),6.52(d, J=8.4Hz,1H,ArH),5.61(s,2H,NCH2),3.73-3.58(m,8H,哌嗪-H).13C NMR(100MHz, DMSO-d6)δ162.45,161.51,158.45,137.70,135.26,133.02,132.86,131.88,129.87,129.21,128.00,126.53,124.08,122.16,121.03,111.05,110.99,105.05,45.09,43.71.ESI-HRMS(m/z): [M+H]+C24H21Cl2N5O:理论值466.1201,实测值466.1184.
实施例15:化合物(1-(4-氟苄基)-5-甲氧基-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮 (I-15)的制备
参考实施例1的制备方法,将实施例1化合物3替换为5-甲氧基吲哚-2-甲酸,制得白色固体状化合物I-15,最后一步收率59.3%。m.p.167.8℃-169.4℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.7Hz,2H,ArH),7.51(d,J=9.0Hz,1H,ArH),7.20-7.05(m,5H,ArH),6.89(dd,J=9.0,2.5Hz,1H,ArH),6.74-6.64(m,2H,ArH),5.48(s,2H,NCH2),3.77(s,3H,OCH3),3.74-3.39(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.84,161.81 (1JC-F=241.7Hz),161.49,158.46,154.66,135.10(4JC-F=3.1Hz),132.78,132.19,129.46 (3JC-F=8.3Hz),126.96,115.74(2JC-F=21.1Hz),114.40,112.04,111.03,104.23,102.91,55.81,46.68,43.65.ESI-HRMS(m/z):[M+H]+C25H24FN5O2:理论值446.1992,实测值446.1986.
实施例16:化合物(1-(4-甲氧基苄基)-5-甲氧基-1H-吲哚-2-基)(4-(嘧啶-2-基)哌嗪-1-基) 甲酮(I-16)的制备
参考实施例1的制备方法,将实施例1化合物3替换为5-甲氧基吲哚-2-甲酸,将4-氟氯苄替换为4-甲氧基氯苄,制得白色固体状化合物I-16,最后一步收率55.7%。m.p.139.3℃-140.2℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.7,2H,ArH),7.53(d,J=8.9 Hz,1H,ArH),7.12-7.10(m,1H,ArH),7.05-7.01(m,2H,ArH),6.90-6.86(m,1H,ArH), 6.84-6.75(m,2H,ArH),6.72-6.60(m,2H,ArH),5.39(s,2H,NCH2),3.77(m,6H,OCH3), 3.65-3.56(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.98,161.56,158.99,158.43, 154.57,132.82,132.24,130.84,128.89,126.92,114.36,114.23,112.06,111.03,103.96,102.85,55.81,55.44,46.79,43.62.ESI-HRMS(m/z):[M+H]+C26H27N5O3:理论值458.2192,实测值458.2175.
实施例17:化合物(5-氯-1-(4-氟苄基)-1H-吲哚-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-17) 的制备
参考实施例1的制备方法,将实施例1化合物3替换为5-氯吲哚-3-甲酸,制得白色固体状化合物I-17,最后一步收率62.7%。m.p.176.3℃-177.4℃;1H NMR(400MHz, DMSO-d6)δ8.40(d,J=4.7Hz,2H,ArH),8.11(s,1H,ArH),7.80(d,J=2.0Hz,1H,ArH), 7.58(d,J=8.8Hz,1H,ArH),7.38-7.34(m,2H,ArH),7.23-7.15(m,3H,ArH),6.67(t,J=4.7 Hz,1H,ArH),5.49(s,2H,NCH2),3.86-3.81(m,4H,哌嗪-H),3.79-3.74(m,4H,哌嗪-H). 13C NMR(100MHz,DMSO-d6)δ164.99,162.07(1JC-F=242.1Hz),161.65,158.46,134.46, 133.91(4JC-F=3.1Hz),133.29,129.89(3JC-F=8.1Hz),128.74,126.03,122.74,120.46,115.96(2JC-F=21.4Hz),112.94,110.89,109.24,49.26,43.96.ESI-HRMS(m/z):[M+H]+C24H21ClN5O:理论值450.1497,实测值450.1499.
实施例18:化合物(5-氯-1-(4-甲氧基苄基)-1H-吲哚-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-18)的制备
参考实施例1的制备方法,将实施例1化合物3替换为5-氯吲哚-3-甲酸,将4-氟氯苄替换为4-甲氧基氯苄,制得白色固体状化合物I-18,最后一步收率63.3%。m.p. 169.1℃-170.2℃;1H NMR(400MHz,DMSO-d6)δ8.40(d,J=4.7Hz,2H,ArH),8.08(s,1H, ArH),7.79(d,J=2.0Hz,1H,ArH),7.58(d,J=8.8Hz,1H,ArH),7.27(d,J=8.7Hz,2H,ArH), 7.20(dd,J=8.8,2.1Hz,1H,ArH),6.89(d,J=8.7Hz,2H,ArH),6.67(t,J=4.7Hz,1H,ArH), 5.41(s,2H,NCH2),3.85-3.81(m,4H,哌嗪-H),3.77-3.73(m,4H,哌嗪-H),3.71(s,3H, OCH3).13CNMR(100MHz,DMSO-d6)δ165.07,161.65,159.25,158.46,134.45,133.25, 129.53,129.26,128.72,125.92,122.60,120.39,114.51,113.02,110.89,109.02,55.53,49.56,43.96.ESI-HRMS(m/z):[M+H]+C25H24ClN5O2:理论值462.1697,实测值462.1679.
实施例19:化合物(5-氯-1-(3-氟苄基)-1H-吲哚-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-19) 的制备
参考实施例1的制备方法,将实施例1化合物3替换为5-氯吲哚-3-甲酸,将4-氟氯苄替换为3-氟氯苄,制得白色固体状化合物I-19,最后一步收率61.6%。m.p. 156.7℃-158.4℃;1H NMR(400MHz,DMSO-d6)δ8.40(d,J=4.7Hz,2H,ArH),8.12(s,1H, ArH),7.81(d,J=2.0Hz,1H,ArH),7.57(d,J=8.8Hz,1H,ArH),7.41-7.34(m,1H,ArH), 7.22(dd,J=8.8,2.1Hz,1H,ArH),7.18-7.08(m,3H,ArH),6.67(t,J=4.7Hz,1H,ArH),5.52 (s,2H,NCH2),3.87-3.81(m,4H,哌嗪-H),3.80-3.73(m,4H,哌嗪-H).13C NMR(100MHz, DMSO-d6)δ164.97,162.70(1JC-F=242.6Hz),161.66,158.45,140.55(3JC-F=7.2Hz),134.54, 133.39,131.22(3JC-F=8.3Hz),128.73,126.10,123.71(4JC-F=2.9Hz),122.83,120.49,114.99 (2JC-F=20.8Hz),114.58(2JC-F=21.6Hz),112.91,110.90,109.36,49.46,43.96.ESI-HRMS (m/z):[M+H]+C24H21ClN5O:理论值450.1497,实测值450.1498.
实施例20:化合物(5-氯-1-(3-甲氧基苄基)-1H-吲哚-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮 (I-20)的制备
参考实施例1的制备方法,将实施例1化合物3替换为5-氯吲哚-3-甲酸,将4-氟氯苄替换为3-甲氧基氯苄,制得白色固体状化合物I-20,最后一步收率53.6%。m.p. 148.2℃-149.1℃;1H NMR(400MHz,DMSO-d6)δ8.40(d,J=4.7Hz,2H,ArH),8.10(s,1H, ArH),7.79(d,J=1.8Hz,1H,ArH),7.57(d,J=8.8Hz,1H,ArH),7.27-7.19(m,2H,ArH), 6.90-6.79(m,3H,ArH),6.68(t,J=4.8Hz,1H,ArH),5.46(s,2H,NCH2),3.87-3.81(m,4H, 哌嗪-H),3.78-3.74(m,4H,哌嗪-H),3.72(s,3H,OCH3).13C NMR(100MHz,DMSO)δ 165.05,161.66,159.92,158.45,139.21,134.61,133.43,130.30,128.68,125.99,122.71,120.42, 119.74,113.72,113.25,112.99,110.90,109.15,55.52,49.98,43.95.ESI-HRMS(m/z):[M+H]+C25H24ClN5O:理论值462.1697,实测值462.1701.
实施例21:化合物(5-氯-1-(2,4-二氯苄基)-1H-吲哚-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮 (I-21)的制备
参考实施例1的制备方法,将实施例1化合物3替换为5-氯吲哚-3-甲酸,将4-氟氯苄替换为2,4-二氯氯苄,制得白色固体状化合物I-21,最后一步收率51.6%。m.p. 183.6℃-185.0℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.7Hz,2H,ArH),8.00(s,1H, ArH),7.83(d,J=2.0Hz,1H,ArH),7.70(d,J=2.1Hz,1H,ArH),7.49(d,J=8.8Hz,1H,ArH), 7.36(dd,J=8.4,2.1Hz,1H,ArH),7.22(dd,J=8.8,2.1Hz,1H,ArH),6.79(d,J=8.4Hz,1H, ArH),6.67(t,J=4.7Hz,1H,ArH),5.59(s,2H,NCH2),3.85-3.80(m,4H,哌嗪-H),3.79-3.73 (m,4H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ164.86,161.65,158.45,134.72,134.19, 133.61,133.46,133.29,130.22,129.56,128.62,128.31,126.23,123.02,120.56,112.79,110.90,109.61,47.52,43.94.ESI-HRMS(m/z):[M+H]+C24H20Cl3N5O:理论值500.0812,实测值500.0818.
实施例22:化合物(1-(4-氟苄基)-1H-吲哚-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-22)的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲哚-3-甲酸,制得白色固体状化合物I-22,最后一步收率55.9%。m.p.136.4℃-138.1℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.7Hz,2H,ArH),8.01(s,1H,ArH),7.76(d,J=7.6Hz,1H,ArH),7.53(d,J=8.0Hz,1H,ArH),7.38-7.33(m,2H,ArH),7.21-7.11(m,4H,ArH),6.67(t,J=4.7Hz,1H,ArH),5.47(s,2H,NCH2),3.87-3.79(m,4H,哌嗪-H),3.77-3.69(m,4H,哌嗪-H).13C NMR(100 MHz,DMSO-d6)δ165.70,162.01(1JC-F=242.1Hz),161.66,158.46,135.90,134.22(4JC-F=3.2Hz),131.94,129.89(3JC-F=8.3Hz),127.27,122.66,121.15,121.13,115.90(2JC-F=21.4 Hz),111.25,110.89,109.78,49.06,44.02.ESI-HRMS(m/z):[M+H]+C24H22FN5O:理论值416.1887,实测值416.1871.
实施例23:化合物(1-(4-甲氧基苄基)-1H-吲哚-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-23) 的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲哚-3-甲酸,将4-氟氯苄替换为4-甲氧基氯苄,制得白色固体状化合物I-23,最后一步收率52.3%。m.p. 131.6℃-133.2℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.7Hz,2H,ArH),7.97(s,1H, ArH),7.75(d,J=7.7Hz,1H,ArH),7.54(d,J=8.1Hz,1H,ArH),7.27(d,J=8.6Hz,2H,ArH), 7.20-7.10(m,2H,ArH),6.89(d,J=8.7Hz,2H,ArH),6.66(t,J=4.7Hz,1H,ArH),5.39(s,2H, NCH2),3.85-3.80(m,4H,哌嗪-H),3.76-3.71(m,4H,哌嗪-H),3.70(s,3H,OCH3).13C NMR (100MHz,DMSO-d6)δ165.78,161.67,159.18,158.46,135.90,131.92,129.85,129.29, 127.24,122.52,121.08,121.02,114.47,111.34,110.89,109.56,55.53,49.35,44.02. ESI-HRMS(m/z):[M+H]+C25H25N5O2:理论值428.2087,实测值428.2077.
实施例24:化合物(1-(3-氟苄基)-1H-吲哚-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-24)的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲哚-3-甲酸,将4-氟氯苄替换为3-氟氯苄,制得白色固体状化合物I-24,最后一步收率56.5%。m.p.152.7℃-154.0℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.7Hz,2H,ArH),8.02(s,1H,ArH),7.78(d,J=7.5Hz,1H,ArH),7.53(d,J=8.0Hz,1H,ArH),7.40-7.34(m,1H,ArH),7.21-7.08(m,5H,ArH),6.66(t,J=4.7Hz,1H,ArH),5.51(s,2H,NCH2),3.87-3.80(m,4H,哌嗪-H),3.78-3.72(m,4H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ164.96,162.69(1JC-F=242.7Hz),161.65,158.46,140.55(3JC-F=7.1Hz),134.53,133.40,131.23(3JC-F=8.3Hz),128.72,126.09,123.72 (4JC-F=2.8Hz),122.82,120.49,114.99(2JC-F=20.7Hz),114.59(2JC-F=21.6Hz),112.91, 110.89,109.34,49.45,43.95.ESI-HRMS(m/z):[M+H]+C24H22FN5O:理论值416.1887,实测值416.1878.
实施例25:化合物(1-(3-甲氧基苄基)-1H-吲哚-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-25) 的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲哚-3-甲酸,将4-氟氯苄替换为3-甲氧基氯苄,制得白色固体状化合物I-25,最后一步收率59.2%。m.p. 104.2℃-105.7℃;1H NMR(400MHz,DMSO-d6)δ8.39(d,J=4.5Hz,2H,ArH),8.00(s,1H, ArH),7.77(d,J=7.6Hz,1H,ArH),7.53(d,J=7.9Hz,1H,ArH),7.27-7.11(m,3H,ArH), 6.89(s,1H,ArH),6.83(t,J=7.7Hz,2H,ArH),6.66(t,J=4.5Hz,1H,ArH),5.45(s,2H, NCH2),3.87-3.81(m,4H,哌嗪-H),3.78-3.72(m,4H,哌嗪-H),3.71(s,3H,OCH3).13C NMR (100MHz,DMSO-d6)δ165.76,161.67,159.89,158.45,139.54,136.05,132.11,130.25, 127.20,122.62,121.10,120.92,119.80,113.75,113.11,111.30,110.89,109.70,55.49,49.77,44.01.ESI-HRMS(m/z):[M+H]+C25H25N5O2:理论值428.2087,实测值428.2089.
实施例26:化合物(1-(2,4-二氯苄基)-1H-吲哚-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-26) 的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲哚-3-甲酸,将4-氟氯苄替换为2,4-二氯氯苄,制得白色固体状化合物I-26,最后一步收率59.2%。m.p. 176.1℃-178.0℃;1H NMR(400MHz,DMSO-d6)δ8.40(d,J=4.7Hz,2H,ArH),8.13(s,1H, ArH),7.81(d,J=2.0Hz,1H,ArH),7.58(d,J=8.8Hz,1H,ArH),7.41-7.38(m,1H,ArH), 7.22(dd,J=8.8,2.1Hz,1H,ArH),7.19-7.08(m,3H,ArH),6.67(t,J=4.7Hz,1H,ArH),5.53 (s,2H,NCH2),3.88-3.82(m,4H,哌嗪-H),3.80-3.72(m,4H,哌嗪-H).13C NMR(100MHz, DMSO-d6)δ164.85,161.64,158.45,134.72,134.20,133.60,133.47,133.29,130.20,129.57, 128.62,128.32,126.22,123.02,120.55,112.80,110.90,109.59,47.51,43.93.ESI-HRMS(m/z):[M+H]+C24H21Cl2N5O:理论值466.1201,实测值466.1206.
实施例27:化合物(1-(4-氟苄基)-1H-吲唑-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-27)的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲唑-3-甲酸,制得黄色固体状化合物I-27,最后一步收率55.9%。m.p.143.2℃-144.9℃;1H NMR(400MHz,DMSO-d6)δ8.40(d,J=4.7Hz,2H,ArH),8.01(d,J=8.2Hz,1H,ArH),7.84(d,J=8.5Hz,1H,ArH),7.47(t,J=7.7Hz,1H,ArH),7.41-7.35(m,2H,ArH),7.26(t,J=7.4Hz,1H,ArH),7.21-7.15(m,J= 8.9Hz,2H,ArH),6.68(t,J=4.7Hz,1H,ArH),5.75(s,2H,NCH2),4.11-3.78(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.20,162.13(1JC-F=242.3Hz),161.60,160.92,158.45,140.15,138.39,133.53(4JC-F=3.0Hz),130.25(3JC-F=8.3Hz),127.43,124.18,122.67, 122.26,115.95(2JC-F=21.3Hz),110.93,110.76,51.95,46.70,44.31,43.63,42.25.ESI-HRMS (m/z):[M+H]+C23H21FN5O:理论值417.1839,实测值417.1820.
实施例28:化合物(1-(4-甲氧基苄基)-1H-吲唑-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-28) 的制备
参考实施例1的合成方法,将实施例1化合物3替换为吲唑-3-甲酸,将4-氟氯苄替换为4-甲氧基氯苄,制得白色固体状化合物I-28,最后一步收率52.3%。m.p. 101.7℃-103.1℃;1H NMR(400MHz,DMSO-d6)δ8.40(d,J=4.7Hz,2H,ArH),7.99(d,J= 8.1Hz,1H,ArH),7.81(d,J=8.5Hz,1H,ArH),7.45(t,J=7.6Hz,1H,ArH),7.32-7.20(m,3H, ArH),6.89(d,J=8.5Hz,2H,ArH),6.68(t,J=4.7Hz,1H,ArH),5.66(s,2H,NCH2), 4.09-3.79(m,8H,哌嗪-H),3.71(s,3H,OCH3).13C NMR(100MHz,DMSO-d6)δ162.27, 161.62,159.33,158.45,140.01,138.10,129.58,129.19,127.26,124.25,122.56,122.23,114.50,110.93,110.86,55.53,52.34,46.71,44.33,43.65,42.27.ESI-HRMS(m/z):[M+H]+C24H24N6O2:理论值429.2039,实测值429.2022.
实施例29:化合物(1-(3-氟苄基)-1H-吲唑-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-29)的制备
参考实施例1的合成方法,将实施例1化合物3替换为吲唑-3-甲酸,将4-氟氯苄替换为3-氟氯苄,制得白色固体状化合物I-29,最后一步收率56.5%。m.p.110.1℃-111.6℃;1H NMR(400MHz,DMSO-d6)δ8.40(d,J=4.7Hz,2H,ArH),8.02(d,J=8.2Hz,1H,ArH), 7.84(d,J=8.5Hz,1H,ArH),7.52-7.45(m,1H,ArH),7.43-7.36(m,1H,ArH),7.28(t,J=7.5 Hz,1H,ArH),7.20-7.09(m,3H,ArH),6.67(t,J=4.7Hz,1H,ArH),5.79(s,2H,NCH2), 4.10-3.78(m,8H,哌嗪-H).13C NMR(100MHz,DMSO-d6)δ162.61(1JC-F=242.8Hz), 162.19,161.61,158.44,140.31,140.09(3JC-F=7.2Hz),138.57,131.22(3JC-F=8.2Hz),127.52,124.14,124.05(4JC-F=2.7Hz),122.72,122.28,115.18,114.97,114.89(2JC-F=21.7Hz),110.82(2JC-F=20.2Hz),52.10,46.69,44.29,43.63,42.26.ESI-HRMS(m/z):[M+H]+C23H21FN5O:理论值417.1839,实测值417.1820.
实施例30:化合物(1-(3-甲氧基苄基)-1H-吲唑-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-30) 的制备
参考实施例1的制备方法,将实施例1化合物3替换为吲唑-3-甲酸,将4-氟氯苄替换为3-甲氧基氯苄,制得白色固体状化合物I-30,最后一步收率59.2%。m.p. 144.0℃-145.5℃;1H NMR(400MHz,DMSO-d6)δ8.40(d,J=4.7Hz,2H,ArH),8.01(d,J= 8.2Hz,1H,ArH),7.81(d,J=8.5Hz,1H,ArH),7.49-7.43(m,1H,ArH),7.28-7.22(m,2H, ArH),6.90(s,1H,ArH),6.87–6.81(m,2H,ArH),6.67(t,J=4.7Hz,1H,ArH),5.72(s,2H, NCH2),4.12-3.79(m,8H,哌嗪-H),3.71(s,3H,OCH3).13C NMR(100MHz,DMSO-d6)δ 162.24,161.61,159.84,158.46,140.26,138.82,138.29,130.28,127.38,124.16,122.64,122.24,120.05,113.91,113.40,110.94,110.82,55.49,52.67,46.67,44.30,43.63,42.26.ESI-HRMS (m/z):[M+H]+C24H24N6O2:理论值429.2039,实测值429.2096.
实施例31:化合物(1-(2,4-二氯苄基)-1H-吲唑-3-基)(4-(嘧啶-2-基)哌嗪-1-基)甲酮(I-31) 的制备
参考实施例1的制备方法,将化合物3替换为吲唑-3-甲酸,将4-氟氯苄替换为2,4-二氯氯苄,制得白色固体状化合物I-31,最后一步收率59.2%。m.p.177.4℃-179.1℃;1HNMR(400MHz,DMSO-d6)δ8.39(d,J=4.7Hz,2H,ArH),8.02(d,J=8.1Hz,1H,ArH),7.81 (d,J=8.5Hz,1H,ArH),7.71(d,J=1.9Hz,1H,ArH),7.49(t,J=7.6Hz,1H,ArH),7.42(dd, J=8.3,1.8Hz,1H,ArH),7.29(t,J=7.5Hz,1H,ArH),7.10(d,J=8.4Hz,1H,ArH),6.67(t, J=4.7Hz,1H,ArH),5.81(s,2H,NCH2),4.04-3.76(m,8H,哌嗪-H).13C NMR(100MHz, DMSO-d6)δ165.78,161.67,159.18,158.46,135.90,131.92,129.85,129.29,127.24,122.52,121.08,121.02,114.47,111.34,110.89,109.56,55.53,49.98.ESI-HRMS(m/z):[M+H]+C23H20Cl2N6O:理论值467.1154,实测值467.1139.
实施例32生物活性测试
实验材料
实验细胞系:
BV2小鼠小胶质细胞,购自武汉普诺赛(中国武汉)。
试剂与仪器:
常用生物试剂:DMEM培养基(Gibco,Grand Island,NY,USA);葡萄糖(Glucose,Glu, 国药集团化学试剂有限公司);胎牛血清(Fetal bovine serum,FBS,Hyclone,Logan,UT, USA);MTT溶液(5mg/mL)(生兴生物技术有限公司);IL-1βElisa、IL-6Elisa、TNF-αElisa和PGE2 Elisa试剂盒(BOSTER Biological Technology co.ltd,China);一氧化氮检测试剂盒(beyotime,Shanghai,China)。
常用仪器:三气培养箱,Thermo公司;Forma 3111型水套式CO2培养箱:ThermoElectron company;Berthold LB941微孔板式多功能酶标仪,Berthold公司。
1)本发明化合物对BV2细胞缺氧复氧损伤的保护
选取对数生长期的BV2细胞建立体外OGD/R模型。调节细胞密度,以4×104的细胞密度接种于96孔培养板中,使用含有1μM浓度待测化合物的DMEM培养基(含1%FBS) 培养BV2细胞,于37℃、5%CO2培养箱中培养24h。24h后将培养基更换成不含葡萄糖与胎牛血清的DMEM培养基,并置于37℃且含有5%CO2、95%N2三气培养箱中培养2h;完成缺氧过程后,将培养基换成含有10%FBS的DMEM培养基。然后将BV2细胞放回37℃且含有5%CO2的正常培养箱中进行培养24h完成复氧过程。孵育结束前4h,每孔加入20μL MTT溶液(5mg/mL)。孵育结束后,弃去各孔上清液,每孔加入150μL DMSO,细胞振荡仪上振荡10min,待结晶物充分溶解后用酶标仪测定OD 570。结果如表1所示。所使用的阳性对照为Minozac、化合物1和化合物2。
表1化合物对OGD/R诱导的BV2细胞损伤的保护
注:药物处理组与OGD/R组相比,*P<0.05,**P<0.01;与化合物1相比,aP<0.05,aaP<0.01;与化合物2相比,bP<0.05,bbP<0.01;与Minozac组相比,cP<0.05,ccP<0.01。
由表1可知,与模型组相比,本发明化合物在1μM下可明显提高细胞存活率。在1μM下,化合物I-1、I-4、I-6~I-8、I-10~I-14、I-16、I-18~I-20、I-22~I-31对OGD/R诱导的BV2细胞的保护作用明显优于阳性药1、2和Minozac;其余化合物对OGD/R诱导的BV2 细胞的保护作用和阳性化合物相当。
2)本发明化合物对LPS诱导的BV2细胞释放促炎因子的影响
将对数生长期BV2细胞以1×105个细胞/孔接种于96孔板,置于37℃,5%CO2条件下培养,直至细胞90%融合后,用无胎牛血清的DMEM培养基于37℃、5%CO2下培养2h使细胞同步化。随后,弃去上清液,分别加入浓度为10μM的本发明化合物或阳性对照化合物,于在37℃、5%CO2培养箱中孵育BV2细胞2h后,将培养基更换为含 LPS(200ng/ml)的培养基继续孵育8h。不加LPS和化合物以及不加化合物只加入LPS处理的细胞分别作为空白对照组和LPS对照组。孵育结束后,收集细胞上清液,-80℃冻存备用。
分别根据ELISA试剂盒说明检测细胞上清液中TNF-α、IL-1β、IL-6、PGE2的水平。
使用一氧化氮检测试剂盒测定NO含量:取50μl的细胞培养上清液加入96孔板中,再加入50μl的Griess试剂(以5%磷酸配制的1%对氨基苯磺酸溶液,以蒸馏水配制的0.1%萘乙二胺溶液,使用时将二者1∶1等体积混合),室温下反应15min,使用酶标仪测定540nm处吸光度。每个试验重复5次。实验数据见表2。
表2化合物对LPS诱导的BV2细胞释放促炎因子的影响
ND:表示未检测。
注:与吲哚美辛组相比:*P<0.05,**P<0.01;与化合物1组相比,aP<0.05,aaP<0.01;与化合物2组相比,bP<0.05,bbP<0.01;与Minozac组相比,cP<0.05,ccP<0.01。
如表2所示,化合物I-10和I-27对TNF-α的抑制活性显著强于阳性对照化合物1、Minozac和吲哚美辛(P<0.05)。I-10和I-27对IL-1β、IL-6和PGE2的抑制活性极显著优于阳性对照化合物1、Minozac和吲哚美辛(P<0.01)。相较于阳性对照化合物2,化合物I-10 和I-27显示出明显的IL-6和PGE2抑制活性(P<0.05)。选择化合物I-10测试其抑制NO 生成活性,结果显示化合物I-10对NO的抑制活性显著强于吲哚美辛(P<0.01)。
3)本发明化合物对OGD/R诱导的BV2细胞表型分化的影响
选取对数生长期的BV2细胞,以4×104的细胞密度接种于96孔培养板中,于37℃、5%CO2培养箱中,使用DMEM培养基(含10%FBS)培养BV2细胞24h。24h后将培养基更换成不含葡萄糖与胎牛血清的DMEM(含10%FBS)培养基,并置于37℃且含有5% CO2、95%N2三气培养箱中培养2h完成缺氧过程,2h后将培养基换成含或不含I-10(0.1、 1和10μM)的DMEM培养基(含10%FBS),于37℃、5%CO2的培养箱中培养24h,同时完成复氧过程。24h后,收集细胞,用4℃预冷的PBS清洗。在4℃下,1000r/min离心5min,弃去上清液。然后向剩余物中加入PBS重悬,调整细胞密度至1×106/ml。M1 检测加入IBA-1(1:400)和CD16/32(1:400)工作液到每100μL的细胞悬液中,M2检测加入IBA-1(1:400)和CD206(1:400)。混匀,置于4℃下避光孵育30min,用PBS缓冲液洗涤2遍后,加入500μl的PBS缓冲液重悬细胞,使用流式细胞仪检测。以CD16/32作为小胶质细胞M1型标志物,CD206作为M2型标志物,IBA-1作为活化的小胶质细胞标志物。
如图1和2所示,与对照组相比,OGD/R组的CD16/32或CD206的比例显著增加或降低(P<0.01),表明小胶质细胞分化模型建立成功。图1中,与OGD/R组相比,三个浓度(0.1,1和10μM)的I-10均显著降低小胶质细胞中CD16/32的比例(P<0.01)。图2中,与OGD/R组相比,三个浓度(0.1、1和10μM)的I-10均显著增加小胶质细胞中CD206 的比例(P<0.01)。综上所述,I-10可抑制OGD/R诱导的小胶质细胞向M1表型标志物的产生,并促进小胶质细胞M2表型标志物的产生,表明化合物I-10可以使小胶质细胞从促炎表型向抗炎表型转变。
综上所述,本发明化合物具有调控小胶质细胞表型分化的效果,它们能够抑制小胶质细胞向M1表型分化,促进小胶质细胞向M2表型分化,证明此类化合物抗神经炎症、发挥神经保护作用是通过调控小胶质细胞表型分化实现的,显示出潜在的研究价值和药用前景,可用于预防和治疗与小胶质细胞活化相关的神经系统疾病。
Claims (13)
1.具有如式(I)或式(I’)所示结构的化合物,
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,
其中:
B1、B2、B3、B4各自独立地选自CH或N;
X选自CH或N;
R1选自
R2、R3、R4、R7各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基、-ORa、-SRa、-CORa、-CO2Ra、-SORa、-SO2Ra、-NRaRb、-CONRaRb、-SO2NRaRb、-NRaCORb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基、C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基,或者,Ra和Rb与其共同连接的氮原子一起形成5至14元含氮杂环;
R5选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-NRaRb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基,或者,Ra和Rb与其共同连接的氮原子一起形成5至14元含氮杂环;
R6选自任选取代的C1-C20烷基、C2-C20烯基、C2-C20炔基、C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基;其中,所述C1-C20烷基、C2-C20烯基、C2-C20炔基任选地被选自以下的基团取代:卤素、羟基、氰基、硝基、C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基;所述C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基任选地被选自以下的基团取代:C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-CORa、-CO2Ra、-SORa、-SO2Ra、-NRaRb、-CONRaRb、-SO2NRaRb、-NRaCORb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基,或者,Ra和Rb与其共同连接的氮原子一起形成5至14元含氮杂环;
Z选自O、S、NR8;
R8选自H、C1-C20烷基;
m、m’、n、p各自独立地为选自0、1、2、3、4、5的整数。
2.根据权利要求1所述的化合物,其为式(II)或式(II’)所示的化合物,
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,
其中:
B1、B2、B3、B4、R2、R3、R4、R5、R6、R7、m、m’、n、p如权利要求1中所定义。
3.根据前述权利要求所述的化合物,或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,
其中:
R2、R3、R4、R7各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-CORa、-CO2Ra、-SORa、-SO2Ra、-NRaRb、-CONRaRb、-SO2NRaRb、-NRaCORb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基、C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基,或者,Ra和Rb与其共同连接的氮原子一起形成5至14元含氮杂环;优选地,R2、R3、R4、R7各自独立地选自H、C1-C20烷基、卤素、C1-C20卤代烷基、-ORa、-SRa、-NRaRb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基。
4.根据前述权利要求所述的化合物,或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,
其中:
R6选自任选取代的C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基;其中所述C3-C20环烷基、C6-C14芳基、5至14元杂芳基、5至14元杂环基任选地被选自以下的基团取代:C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-CORa、-CO2Ra、-SORa、-SO2Ra、-NRaRb、-CONRaRb、-SO2NRaRb、-NRaCORb;Ra和Rb各自独立地选自H、C1-C20烷基、C2-C20烯基、C2-C20炔基、C1-C20卤代烷基,或者,Ra和Rb与其共同连接的氮原子一起形成5至14元含氮杂环;
优选地,R6选自任选取代的C6-C14芳基、5至14元杂芳基;其中所述C6-C14芳基、5至14元杂芳基任选地被选自以下的基团取代:C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-CORa、-CO2Ra、-SORa、-SO2Ra、-NRaRb、-CONRaRb、-SO2NRaRb、-NRaCORb;Ra和Rb各自独立地选自H、C1-C20烷基、C1-C20卤代烷基;
更优选地,R6选自任选取代的苯基、萘基、蒽基、吡咯基、咪唑基、吡唑基、呋喃基、噻吩基、噁唑基、噻唑基、三唑基、吡啶基、嘧啶基、吡嗪基、哒嗪基、吲哚基、吲唑基、喹啉基、异喹啉基、喹唑啉基、异噁唑基、呋喃基、噁二唑基、噻二唑基、苯并噻唑基、苯并噁唑基、喹喔啉基、5,6,7,8-四氢异喹啉基、苯并呋喃基、苯并咪唑基、硫杂茚基、吡咯并[2,3-b]吡啶基、喹唑啉基-4(3H)-酮、4,5,6,7-四氢-1H-吲唑基、3b,4,4a,5-四氢-1H-环丙烷[3,4]环戊烷[1,2-c]吡唑基;上述基团任选地被选自以下的基团取代:C1-C20烷基、C2-C20烯基、C2-C20炔基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-NRaRb;Ra和Rb各自独立地选自H、C1-C20烷基、C1-C20卤代烷基。
5.根据前述权利要求所述的化合物,或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,
其中:
R5选自H、C1-C20烷基、卤素、C1-C20卤代烷基、氰基、硝基、-ORa、-SRa、-NRaRb;Ra和Rb各自独立地选自H、C1-C20烷基、C1-C20卤代烷基。
6.根据前述权利要求所述的化合物,其为具有如式(III)、(III’)或(III”)所示结构的化合物
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,其中,B1、B2、B3、B4、R2、R3、R4、R5、R6、R7、m、m’、n、p如前述权利要求所定义。
7.根据前述权利要求所述的化合物,其为具有如式(IV)、(IV’)或(IV”)所示结构的化合物
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,其中,R2、R3、R4、R5、R6、R7、m、m’、n、p如前述权利要求所定义。
8.根据权利要求1所述的化合物,其为具有如式(V)、(V’)或(V”)所示结构的化合物
或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,其中,R2、R3、R4、R5、R6、R7、n、p如前述权利要求所定义。
9.根据权利要求1所述的化合物,选自:
10.根据权利要求1-9中任一项所述化合物的制备方法,包括:
式(II-a)所示化合物与式(1)所示的胺在适合形成酰胺的条件下反应得到式(II)所示的酰胺,或者,
式(II’-a)所示化合物与式(1)所示的胺在适合形成酰胺的条件下反应得到式(II’)所示的酰胺。
11.一种药物组合物,其包含根据权利要求1-9中任一项所述化合物或其药学上可接受的盐、互变异构体、立体异构体、前药、溶剂合物,和药学上可接受的载体,优选地,所述药物组合物还包含另外的用于治疗神经相关疾病的治疗剂,所述治疗剂可以选自溶栓药物、NMDA受体拮抗剂、抗血小板聚集药物、抗氧化药物、抗凝血药物和抗凋亡药物中的一种或多种。
12.根据权利要求1-9中任一项所述的化合物在制备用于预防和/或治疗神经炎症的药物中的用途。
13.根据权利要求1-9中任一项所述的化合物在制备用于预防和/或治疗与小胶质细胞活化相关的神经系统疾病的药物中的用途,优选所述与小胶质细胞活化相关的神经系统疾病选自缺血性脑卒中、后循环脑缺血、缺血再灌注损伤、肌萎缩性侧索硬化、癫痫、Creutzfeldt-Jakob病、唐氏综合症、扩散性Lewy Body病、亨廷顿病、阿尔兹海默症、多发性硬化、多系统萎缩症、帕金森综合征、原发性脊髓侧索硬化外周神经病、糖尿病性神经病变。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210471801.0A CN117003739A (zh) | 2022-04-29 | 2022-04-29 | 含氮杂环化合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210471801.0A CN117003739A (zh) | 2022-04-29 | 2022-04-29 | 含氮杂环化合物及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117003739A true CN117003739A (zh) | 2023-11-07 |
Family
ID=88562336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210471801.0A Pending CN117003739A (zh) | 2022-04-29 | 2022-04-29 | 含氮杂环化合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117003739A (zh) |
-
2022
- 2022-04-29 CN CN202210471801.0A patent/CN117003739A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109422755B (zh) | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 | |
CN109071509B (zh) | 作为ROR-γ的调节剂的苯并咪唑衍生物 | |
CA2748251C (en) | Bicyclic heterocyclic compound for use as a sensory neuron specific sodium channel inhibitor | |
TWI776156B (zh) | 作為hdac抑制劑之 3-芳基-4-醯胺基-雙環[4,5,0]異羥肟酸 | |
CN102229605B (zh) | 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂 | |
JP5061097B2 (ja) | 縮合複素環化合物 | |
AU2007292155B2 (en) | Imidazole derivative | |
US20070270411A1 (en) | Novel Diazepine Compounds as Ligands of the Melanocortin 1 and/or 4 Receptors | |
WO2008104524A1 (en) | Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase | |
JPH0649027A (ja) | インドール誘導体 | |
WO2019205983A1 (zh) | 氧杂螺环类化合物及其制备方法和用途 | |
WO2012176763A1 (ja) | 新規インダゾール誘導体 | |
SK50895A3 (en) | 3-indolylpiperidine derivative, method of its preparation, its use for preparation of pharmaceutical composition and pharmaceutical composition containing them | |
JP6088491B2 (ja) | 新規1位置換インダゾール誘導体 | |
JP2020502066A (ja) | キナーゼ阻害剤としての複素環式化合物 | |
TW201418225A (zh) | 咪唑衍生物 | |
CA3199496A1 (en) | Heterocycle derivatives for treating trpm3 mediated disorders | |
CN113412263A (zh) | 氮杂双环取代的氧杂螺环衍生物、其制法与医药上的用途 | |
KR20200013718A (ko) | 바닌 억제제로서의 헤테로방향족 화합물 | |
KR20080065674A (ko) | 신규한 인돌 함유 베타 효능제, 이의 제조 방법 및약제로서의 이의 용도 | |
CN117003739A (zh) | 含氮杂环化合物及其制备方法和用途 | |
US6066657A (en) | Benzofuran-4-carboxamides and their therapeutic use | |
CN108017641B (zh) | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 | |
WO2014054634A1 (ja) | ピリミジン誘導体 | |
CN113717161B (zh) | 含氮饱和杂环化合物及其制备方法、药物组合物和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |